203 related articles for article (PubMed ID: 22067021)
1. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer.
Grönberg M; Fjällskog ML; Jirström K; Janson ET
Acta Oncol; 2012 Mar; 51(3):386-93. PubMed ID: 22067021
[TBL] [Abstract][Full Text] [Related]
2. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
Demir H; Turna H; Can G; Ilvan S
J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
[TBL] [Abstract][Full Text] [Related]
7. Integrin expression and survival in human breast cancer.
Berry MG; Gui GP; Wells CA; Carpenter R
Eur J Surg Oncol; 2004 Jun; 30(5):484-9. PubMed ID: 15135474
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
Dellapasqua S; Maisonneuve P; Viale G; Pruneri G; Mazzarol G; Ghisini R; Mazza M; Iorfida M; Rotmensz N; Veronesi P; Luini A; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
[TBL] [Abstract][Full Text] [Related]
9. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
[TBL] [Abstract][Full Text] [Related]
10. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
11. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
13. [Molecular-biological markers as prognostic factors in breast cancer of I-IIA stage].
Stepanova EV; Zagrekova EI; Ermilova VD; Turbin AD; Petrovichev NN; Vysotskaia IV; Dbar ZhN; Pashchenko NV; Baryshnikov AIu; Lichinitser MR
Arkh Patol; 2003; 65(3):14-8. PubMed ID: 12879604
[TBL] [Abstract][Full Text] [Related]
14. The mRNA expression of inhibitors of DNA binding-1 and -2 is associated with advanced tumour stage and adverse clinical outcome in human breast cancer.
Wazir U; Jiang WG; Sharma AK; Newbold RF; Mokbel K
Anticancer Res; 2013 May; 33(5):2179-83. PubMed ID: 23645773
[TBL] [Abstract][Full Text] [Related]
15. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
16. Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence.
Okroj M; Holmquist E; Nilsson E; Anagnostaki L; Jirström K; Blom AM
Cancer Immunol Immunother; 2015 Apr; 64(4):467-78. PubMed ID: 25618258
[TBL] [Abstract][Full Text] [Related]
17. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
[TBL] [Abstract][Full Text] [Related]
18. HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients.
Seki H; Hayashida T; Jinno H; Hirose S; Sakata M; Takahashi M; Maheswaran S; Mukai M; Kitagawa Y
Ann Surg Oncol; 2012 Jun; 19(6):1831-40. PubMed ID: 22396001
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M
Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
[TBL] [Abstract][Full Text] [Related]
20. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
